Status:
COMPLETED
Optimal Placement Duration of Pancreatic Duct Stent
Lead Sponsor:
DongGuk University
Collaborating Sponsors:
Seoul National University Hospital
Gachon University Gil Medical Center
Conditions:
Cholangitis
Post-ERCP Acute Pancreatitis
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
A randomized controlled trial to determine the optimal placement duration of pancreatic duct stents (PDS) inserted during ERCP: 2 vs 4 weeks
Detailed Description
Endoscopic pancreatic duct stenting has been increasingly used for the treatment of a variety of pancreatic disorders including chronic pancreatitis, pancreatic duct stricture, drainage of pseudocysts...
Eligibility Criteria
Inclusion
- Patients who underwent the pancreatic duct stent placement during ERCP
Exclusion
- Patients who had pancreatic duct stent for the purpose of pancreatic interventions
- Patients who underwent simultaneous bile duct stenting
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT04691674
Start Date
February 1 2021
End Date
August 31 2024
Last Update
December 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dongguk University Ilsan Hospital
Goyang-si, Gyeonggi-do, South Korea, 10326